Yvette Edghill-Smith1, Hana Golding2, Jody Manischewitz2, Lisa R King2, Dorothy Scott3, Mike Bray4, Aysegul Nalca5, Jay W Hooper6, Chris A Whitehouse6, Joern E Schmitz7, Keith A Reimann7
& Genoveffa Franchini11
Animal Models & Retroviral Vaccines Section, National Cancer Institute, 41/D804, Bethesda, Maryland 20892, USA.
2
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 29/232, HFM-345, Bethesda, Maryland 20892, USA.
3
Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29/232, HFM-345, Bethesda, Maryland 20892, USA.
4
Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
5
Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, USA.
6
Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA.
7
Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE-113, 330 Brookline Avenue, Boston, Massachusetts 02215, USA.
Correspondence should be addressed to Genoveffa Franchini franchig@mail.nih.gov
